Maxygen’s Neutropenia Candidate Shows Positive Results In Phase IIa Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.
You may also be interested in...
Sanofi, Maxygen Ink Dengue Virus Vaccine Agreement
$24.5 million-plus licensing deal complements Sanofi’s vaccine work with Maxygen’s technology and could lead to next-generation dengue vaccine, Sanofi tells “The Pink Sheet” DAILY.
Roche/Maxygen Halt Development Of Next-Generation Pegasys Candidate
End of Roche relationship has no financial impact on Maxygen, which plans an update on unpartnered Phase II neutropenia candidate MAXY-G34 for early 2008, firm tells “The Pink Sheet” DAILY.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.